Competitive Profile Matrix identifies a lack of novelty for the GABAA receptor agonists vs. SAGE was incorporated on April 16,and trades on the Nasdaq Global Market.

Headquartered in Cambridge, Massachusetts, it is a clinical-stage biopharmaceutical company engaged in developing and commercializing medicines to treat central nervous system disorders [ ref ].

The company's chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate NMDA receptors. The company originally started with a plan to use its platform of "allosteric receptor modulators" primarily for CNS diseases with large market like schizophrenia, though the company fine-tuned its strategy before its IPO and started focusing its own drug discovery efforts on rare, or specialty CNS disorders with the plan to develop such drugs at a low cost and accelerate timelines by qualifying for things like breakthrough or orphan designations from the FDA.

SAGE, the company's lead product candidate, is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

SAGE, is currently in clinical development for the treatment of super-refractory status epilepticus SRSE; Phase 3postpartum depression PPD; Phase 2major depressive disorder MDD; Phase 2 and essential tremor Phase 2. SAGE, are under investigation in the research stage for GABA indications and NMDA-dysfunction-related disorders.

Status epilepticus, Central nervous system disease, Epilepsy, Postnatal depression, Essential tremor, Psychiatric disorder, Unidentified indication, Anesthesia, Traumatic brain injury, Mood disorder, Pain, Sleep disorder. Small molecule therapeutic, Intravenous formulation, Steroid, Oral formulation, Infusion, Analytical method, Drug screening, Pharmaceutical carrier, Solution. SRSE and SE markets are constituted by a number of direct and indirect competitors.

Of interest, most of the conventional drugs used in SE today have been in use for many decades, and advances in pharmacologic therapy have rather lagged behind advances in basic science and other clinical aspects.

The company's current and direct major competitor is Marinus Pharmaceuticals NASDAQ: MRNSwhose scientific founder has been heavily involved in Sage's research. Marinus Pharmaceuticals' lead compound -ganaxolone- which is a synthetic version of Sage's allopregnanolone, announced disappointing top line results from a Phase 3 study for the treatment of adults with drug-resistant focal onset seizures.

Pipeline Drugs Trials Single Targets with Cannabinoid and GABA Agonists Dominant. Global Epilepsy Pipeline October Based on analysis of the company's trend in earnings per share over the past 5 quarters and operating earnings yield, the company is overvalued when compared to all the companies in the same sector.

Investors have raised some concerns about low performance, poor novelty, high competition and small market size. This report is based on the defensive stock market strategies of possible strategic alternatives for the company following FDA regulatory concerns lodging canton texas trade days experimental SAGE in SSRE Phase 3.

Strategic agreement with other companies and organization to boost its research and drive down the costs. The company's weighted averages of Porter's five forces concentrated mostly on the number of substitutes, which are already available to current patients or futures trading bull spread under clinical investigation, and the number of competitors in SSRE, SE, depression and PPD highly unattractive.

Suppliers, entry and exit earn money via sending sms are in line with the sector. Limited financial resources not adequate infrastructure, operational mistakes, loss of business opportunities, loss of employees, reduced productivity.

EPS reduced from 1. The company's operating earnings yield of Despite a positive book value how much money do paleontologist make share of ROA increased following the IPO from Competitive Profile Matrix CPM is essential to compare the company with competitors in the same industry and sector, such as Marinus Pharmaceuticals. It shows the firm's strong and weak points relative to their competitors.

CPM compares both internal and external audits in the same matrix. The pipeline of next-generation epilepsy drugs displays several novel mechanisms of action and are more specific to single targets. Cannabinoid receptor agonists and GABA receptor agonists are the most advanced. Sage Therapeutics is one among a number of direct competitors like Marinus Pharmaceuticals, GW Pharmaceuticals, Insys Therapeutics and Zynerba Therapeutics.

Marinus PharmaceuticalsGW Pharmaceuticals plc NASDAQ: GWPHInsys Therapeutics, Inc.

4 defensive investing strategies - xelenew.web.fc2.com

INSYZynerba Pharmaceuticals NASDAQ: Although the company is strong on developing high quality small molecule, it languishes on several indexes of CPM, which creates a vacuum in the patent protection and more generally competition and financial soundness.

Any adverse event as the failure of the leading compound SAGE in SRSE and following contingency plan may cause the company to forgo investment in capital or technology, or it may perform below its potential. There is a significant weakness and threats from competitors. The company should strengthen its competitive position in a fast growing market where direct competitors and the presence of substitutes undermine potential opportunities.

The Competitive Profile Matrix has showed a lack of novelty for the GABAA receptor agonists in comparison with Cannabinoid receptor agonists and its delivery method. The company should engage in a retrenchment phase and actively operate reduction of cost and assets. I wrote this article myself, and it expresses my own opinions.

I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Defensive Stock

The views, opinions and positions expressed by the author are his alone, and do not necessarily reflect the views, opinions or positions of QStat Consulting or any employee thereof. QStat Consulting make no representations as to accuracy, completeness, timeliness, suitability or validity of any information presented by the author and will not be liable for any errors, omissions, or delays in this information or any losses, injuries or damages arising from its display or use.

Please be aware of the risks associated with these stocks. Defensive Strategies For Sage Therapeutics In The Aftermath Of Potential SAGE Regulatory Action Nov. Summary Sage Therapeutics faces significant threats from competitors. Red flags include a lack of partnerships and public offerings as the only source of funding. SAGE is overvalued and will underperform the market over the next 12 months. Case Abstract Sage Therapeutics NASDAQ: SAGE is also being evaluated in Phase 2 for Parkinson's disease PD and PPD.

How To Build A Defensive Portfolio

Want to share your opinion on this article? Disagree with this article? To report a factual error in this article, click here. Follow Andrea Malizia and get email alerts.